GlassScriptPhysician profile
Joseph A Cook
NPI 1700867199
$3,893.92
in general payments reported to CMS, 2019-2025
25 companies · $888 in 2025
The $888 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $193 · 2020: $102 · 2021: $125 · 2022: $153 · 2023: $1,446 · 2024: $986 · 2025: $888.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,298 · Education: $22.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,297.88 |
| Education | $22.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,528.47 | 2020-2025 | Rinvoq, Skyrizi, Mavyret |
| Intercept Pharmaceuticals, INC. | $443.38 | 2023-2024 | Ocaliva |
| Regeneron Healthcare Solutions, INC. | $263.43 | 2022-2025 | Dupixent |
| Genzyme Corporation | $247.26 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $237.01 | 2022-2025 | Entyvio, Gattex, Eohilia |
| Celgene Corporation | $199.57 | 2023-2024 | Zeposia |
| Janssen Biotech, INC. | $125.98 | 2023-2025 | Stelara, Simponi, Simponi Aria |
| Shire North American Group INC | $122.60 | 2019 | |
| Madrigal Pharmaceuticals | $88.06 | 2024-2025 | Rezdiffra, Resmetirom |
| Ardelyx, INC. | $82.39 | 2023-2025 | Ibsrela |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $76.39 | 2024-2025 | Xifaxan |
| Boston Scientific Corporation | $70.75 | 2019 | |
| Medtronic, INC. | $64.21 | 2021 | |
| Phathom Pharmaceuticals, INC. | $58.82 | 2023-2025 | Voquezna |
| Celltrion USA INC. | $42.72 | 2024-2025 | Vegzelma |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $36.71 | 2023-2025 | |
| Lilly USA, LLC | $33.31 | 2023-2024 | Omvoh |
| Ferring Pharmaceuticals INC. | $30.45 | 2023 | Rebyota |
| Fresenius Kabi USA, LLC | $27.31 | 2024 | Idacio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.92 | 2023 | Cyltezo |
| Pharmacosmos Therapeutics INC. | $22.97 | 2023 | Monoferric |
| Ipsen Biopharmaceuticals, INC | $20.98 | 2024 | Bylvay |
| Aimmune Therapeutics, INC. | $18.65 | 2025 | Zenpep |
| Cook Medical LLC | $13.77 | 2023 | Instinct |
| Braintree Laboratories, INC. | $12.81 | 2023 | Sutab |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Cook listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.